Optiscan Imaging Ltd is a company known for its strong commitment to innovation and excellence in medical imaging. With a vision to improve patient outcomes, Optiscan prides itself on providing cutting-edge solutions for real-time cellular imaging. The company's corporate philosophy revolves around leveraging advanced technology to enhance diagnostic accuracy and enhance the effectiveness of medical procedures. Optiscan Imaging Ltd values integrity, collaboration, and a customer-centric approach, ensuring that their products and services meet the evolving needs of the medical community. By prioritizing research and development, Optiscan aims to revolutionize the field of medical imaging, while maintaining a steadfast dedication to quality and patient care.

Optiscan Imaging Ltd is primarily present in Australia.

Optiscan Imaging Ltd has achieved several significant milestones. The company successfully developed and patented a revolutionary confocal endomicroscopy technology, which enables real-time, high-resolution imaging of living tissue. Optiscan Imaging Ltd also received clearance from the U.S. Food and Drug Administration (FDA) for its confocal endomicroscopy system, facilitating its entry into the American market. Furthermore, the company collaborated with renowned medical institutions and researchers worldwide to conduct clinical studies and validate the efficacy of its imaging technology. Optiscan Imaging Ltd's relentless dedication to innovation and research has positioned it as a leader in the field of real-time tissue imaging.

Optiscan Imaging Ltd is a renowned company specializing in medical imaging technologies. Established in [year], Optiscan has achieved significant milestones in the field of diagnostic imaging. The company is known for its innovative optical imaging systems, such as confocal microscopy, which provide high-resolution cellular images for diagnostic purposes. Optiscan Imaging Ltd has a rich history of research and development, consistently striving to push the boundaries of medical imaging. With its advanced imaging solutions, Optiscan continues to contribute to the progression of healthcare.

The main competitors of Optiscan Imaging Ltd in the market include companies such as Carl Zeiss Meditec AG, NIDEK CO., LTD., and Topcon Corporation.

Optiscan Imaging Ltd is primarily active in the medical technology and healthcare industries.

The business model of Optiscan Imaging Ltd focuses on developing and commercializing advanced medical imaging technologies. The company specializes in the design and manufacture of confocal laser endomicroscopes, which are used in various medical applications. Optiscan Imaging aims to improve the diagnosis and treatment of diseases through their innovative imaging solutions. By leveraging their expertise in advanced imaging technologies, the company aims to provide healthcare professionals with high-quality and real-time cellular imaging during medical procedures. Optiscan Imaging Ltd's business model is centered around offering cutting-edge medical imaging technologies that deliver precise and detailed cellular imaging for improved patient outcomes.

De Optiscan Imaging K/W is -25,80.

De Optiscan Imaging KUV is 135,31.

De AlleAktien Kwaliteitsscore voor Optiscan Imaging is 7/10.

De Optiscan Imaging omzet is 1,16 mln. AUD.

De Optiscan Imaging winst is -6,06 mln. AUD.

Optiscan Imaging Ltd is a leading provider of high-quality microscope systems and components for scientific research, medical diagnostics, and industrial testing and quality assurance. The company was founded in Melbourne, Australia in 1994 and has since expanded its operations worldwide. Today, Optiscan Imaging is a global company that delivers innovative technologies and products to meet the needs of its customers in various industries.

Optiscan Imaging keert een dividend van 0 AUD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Optiscan Imaging of het bedrijf keert geen dividend uit.

De ISIN van Optiscan Imaging is AU000000OIL4.

Het WKN van Optiscan Imaging is 932111.

De ticker van Optiscan Imaging is OIL.AX.

Binnen de laatste 12 maanden betaalde Optiscan Imaging een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Optiscan Imaging naar verwachting een dividend van 0 AUD betalen.

De dividendrendement van Optiscan Imaging is momenteel .

Optiscan Imaging betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Optiscan Imaging betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 AUD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Optiscan Imaging wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Optiscan Imaging van 30-9-2024 ter hoogte van 0 AUD te ontvangen, moest je het aandeel voor de ex-datum op 30-9-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 30-9-2024.

In het jaar 2023 heeft Optiscan Imaging 0 AUD aan dividenden uitgekeerd.

De dividenden van Optiscan Imaging worden in AUD uitgekeerd.